Trichostatin A Targets the Mitochondrial Respiratory Chain, Increasing Mitochondrial Reactive Oxygen Species Production to Trigger Apoptosis in Human Breast Cancer Cells
Aim Histone deacetylase inhibitors (HDACIs)-based therapies have stimulated interest via their anti-tumor activities, including apoptosis induction, cell cycle arrest, cell differentiation, and autophagy. However, the mechanisms of HDACI-associated anti-tumor activity are not yet clearly defined. The aim of this study was to explore the key events of Trichostatin A (TSA), a classic HDACI agent, against breast cancer cells. Methods The MCF-7, MDA-MB-231 and MCF-10A cell lines were evaluated with colony-forming and cell viability assays. Apoptosis and cell cycle distribution were detected by flow cytometry. Mitochondrial function was measured with biochemical assays, flow cytometry and transmission electron microscopy. Results TSA inhibited breast cancer cell viability and proliferation, without affecting MCF-10A cell. TSA-induced breast cancer cell apoptosis was initiated by G2-M arrest and depended on mitochondrial reactive oxygen species (ROS) produced subsequent to reduced mitochondrial respiratory chain activity. The enhanced mitochondrial ROS production and apoptosis in cancer cells were markedly attenuated by antioxidants, such as N-acetyl cysteine (NAC), reduced glutathione (GSH) and Vitamin C. Conclusion The present study demonstrated that TSA-induced cell death by arresting cell cycle in G2-M phase and was dependent on production of mitochondria-derived ROS, which was derived from impaired mitochondrial respiratory chain.
References
[1]
Weigelt B, Peterse JL, van 't Veer LJ (2005) Breast cancer metastasis: markers and models. Nat Rev Cancer 5: 591–602. doi: 10.1038/nrc1670
[2]
Lustberg MB, Ramaswamy B (2011) Epigenetic Therapy in Breast Cancer. Curr Breast Cancer Rep 3: 34–43. doi: 10.1007/s12609-010-0034-0
[3]
Frew AJ, Lindemann RK, Martin BP, Clarke CJ, Sharkey J, et al. (2008) Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci U S A 105: 11317–11322. doi: 10.1073/pnas.0801868105
[4]
Tsuji N, Kobayashi M, Nagashima K, Wakisaka Y, Koizumi K (1976) A new antifungal antibiotic, trichostatin. J Antibiot (Tokyo) 29: 1–6. doi: 10.7164/antibiotics.29.1
[5]
Ma X, Liu J, Wu J, Yan X, Wu P, et al. (2010) Synergistic killing effect between vorinostat and target of CD146 in malignant cells. Clin Cancer Res 16: 5165–5176. doi: 10.1158/1078-0432.ccr-09-3174
[6]
Schmidt K, Gust R, Jung M (1999) Inhibitors of histone deacetylase suppress the growth of MCF-7 breast cancer cells. Arch Pharm (Weinheim) 332: 353–357. doi: 10.1002/(sici)1521-4184(199910)332:10<353::aid-ardp353>3.0.co;2-x
[7]
Wu P, Tian Y, Chen G, Wang B, Gui L, et al. (2010) Ubiquitin B: an essential mediator of trichostatin A-induced tumor-selective killing in human cancer cells. Cell Death Differ 17: 109–118. doi: 10.1038/cdd.2009.142
[8]
Johnstone RW, Licht JD (2003) Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4: 13–18. doi: 10.1016/s1535-6108(03)00165-x
[9]
Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, et al. (2005) Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci U S A 102: 16090–16095. doi: 10.1073/pnas.0505585102
[10]
Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5: 769–784. doi: 10.1038/nrd2133
[11]
Marks PA, Dokmanovic M (2005) Histone deacetylase inhibitors: discovery and development as anticancer agents. Expert Opin Investig Drugs 14: 1497–1511. doi: 10.1517/13543784.14.12.1497
[12]
Rosato RR, Almenara JA, Grant S (2003) The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 63: 3637–3645.
[13]
Ruefli AA, Ausserlechner MJ, Bernhard D, Sutton VR, Tainton KM, et al. (2001) The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A 98: 10833–10838. doi: 10.1073/pnas.191208598
[14]
Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, et al. (2005) Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci U S A 102: 673–678. doi: 10.1073/pnas.0408732102
[15]
Xu W, Ngo L, Perez G, Dokmanovic M, Marks PA (2006) Intrinsic apoptotic and thioredoxin pathways in human prostate cancer cell response to histone deacetylase inhibitor. Proc Natl Acad Sci U S A 103: 15540–15545. doi: 10.1073/pnas.0607518103
[16]
de la Vega L, Grishina I, Moreno R, Kruger M, Braun T, et al. (2012) A redox-regulated SUMO/acetylation switch of HIPK2 controls the survival threshold to oxidative stress. Mol Cell 46: 472–483. doi: 10.1016/j.molcel.2012.03.003
[17]
Sena LA, Chandel NS (2012) Physiological roles of mitochondrial reactive oxygen species. Mol Cell 48: 158–167. doi: 10.1016/j.molcel.2012.09.025
Mo QQ, Chen PB, Jin X, Chen Q, Tang L, et al. (2013) Inhibition of Hec1 expression enhances the sensitivity of human ovarian cancer cells to paclitaxel. Acta Pharmacol Sin 34: 541–548. doi: 10.1038/aps.2012.197
[20]
Zhu Y, Das K, Wu J, Lee MH, Tan P (2013) RNH1 regulation of reactive oxygen species contributes to histone deacetylase inhibitor resistance in gastric cancer cells. Oncogene In Press.
[21]
Alvarez-Fischer D, Fuchs J, Castagner F, Stettler O, Massiani-Beaudoin O, et al. (2011) Engrailed protects mouse midbrain dopaminergic neurons against mitochondrial complex I insults. Nat Neurosci 14: 1260–1266. doi: 10.1038/nn.2916
[22]
Ikeda K, Shiba S, Horie-Inoue K, Shimokata K, Inoue S (2013) A stabilizing factor for mitochondrial respiratory supercomplex assembly regulates energy metabolism in muscle. Nat Commun 4: 2147. doi: 10.1038/ncomms3147
[23]
Stearman RS, Grady MC, Nana-Sinkam P, Varella-Garcia M, Geraci MW (2007) Genetic and epigenetic regulation of the human prostacyclin synthase promoter in lung cancer cell lines. Mol Cancer Res 5: 295–308. doi: 10.1158/1541-7786.mcr-06-0221
Rajendran P, Williams DE, Ho E, Dashwood RH (2011) Metabolism as a key to histone deacetylase inhibition. Crit Rev Biochem Mol Biol 46: 181–199. doi: 10.3109/10409238.2011.557713
[26]
Bernhard D, Ausserlechner MJ, Tonko M, Loffler M, Hartmann BL, et al. (1999) Apoptosis induced by the histone deacetylase inhibitor sodium butyrate in human leukemic lymphoblasts. FASEB J 13: 1991–2001. doi: 10.1038/sj.onc.1202820
[27]
Peart MJ, Smyth GK, van Laar RK, Bowtell DD, Richon VM, et al. (2005) Identification and functional significance of genes regulated by structurally different histone deacetylase inhibitors. Proc Natl Acad Sci U S A 102: 3697–3702. doi: 10.1073/pnas.0500369102
[28]
Johnstone RW (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov 1: 287–299. doi: 10.1038/nrd772
[29]
Gascoigne KE, Taylor SS (2008) Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 14: 111–122. doi: 10.1016/j.ccr.2008.07.002
[30]
Gascoigne KE, Taylor SS (2009) How do anti-mitotic drugs kill cancer cells? J Cell Sci 122: 2579–2585. doi: 10.1242/jcs.039719
[31]
Butler LM, Zhou X, Xu WS, Scher HI, Rifkind RA, et al. (2002) The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A 99: 11700–11705. doi: 10.1073/pnas.182372299
